FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Cook Timothy DeVere 2. Issuer Name and Ticker or Trading Symbol Athenex, Inc. [ ATNX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)
C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600		 3. Date of Earliest Transaction (MM/DD/YYYY)
11/18/2022
(Street)
BUFFALO, NY 14203
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/18/2022    A    2578  A $0.194 (1) 25954  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $17.29                  8/16/2022  8/16/2028  Common Stock  70000    70000  D   
Stock Option (Right to Buy)  $10.26                   (2) 8/27/2030  Common Stock  30000    30000  D   
Stock Option (Right to Buy)  $3.56                   (3) 9/16/2031  Common Stock  9000    9000  D   
Restricted Stock Units   (4)                  (5)  (5) Common Stock  6750    6750  D   
Stock Option (Right to Buy)  $0.6655                   (6) 7/20/2032  Common Stock  75000    75000  D   

Explanation of Responses:
(1)  Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
(2)  This option vests in four equal annual installments beginning on August 27, 2021.
(3)  This option vests in four equal annual installments beginning on September 16, 2022.
(4)  Each restricted stock unit represents a contingent right to receive one share of stock.
(5)  The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
(6)  This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:
Chief Business and Commercial Officer, Proprietary Drugs

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Cook Timothy DeVere
C/O ATHENEX, INC., 1001 MAIN STREET
SUITE 600
BUFFALO, NY 14203

See Remarks

Signatures
/s/Steven Adams, Attorney-in-Fact 11/21/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Athenex Charts.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Athenex Charts.